期刊文献+

乳腺癌分子分型与预后关系的研究 被引量:14

A study on the relationship between breast cancer molecular classification and prognosis
原文传递
导出
摘要 目的探讨乳腺癌分子分型与预后之间的关系。方法回顾性分析2002年1月至2003年12月接受手术治疗的708例原发性乳腺癌患者的临床资料。患者均为女性,平均年龄53岁。根据雌激素受体(ER)、孕激素受体(PR)及人类表皮生长因子受体2(HER2)状态的免疫组织化学结果,将全组乳腺癌分型为:内分泌高反应型、内分泌反应不完全型、三阴型及HER2阳性型,观察不同分子分型乳腺癌的预后,比较各型患者术后的累计生存率,多因素分析筛选预后相关因素。结果本组内分泌高反应型、内分泌反应不完全型、HER2阳性型及三阴型乳腺癌所占的比例分别为33.2%(235/708)、23.6%(167/708)、21.3%(151/708)和21.9%(155/708)。随访3~69个月,中位随访时间40.2个月,100例患者复发或死亡。单因素分析示乳腺癌预后与肿瘤大小、腋窝淋巴结状态、分子分型、术后辅助放疗及内分泌治疗有关;多因素分析示分子分型和淋巴结状态为乳腺癌的独立预后因素;生存分析示内分泌高反应型乳腺癌的预后好于其他三型。结论乳腺癌分子分型是预后的独立预测因素,内分泌高反应型乳腺癌预后最好。 Objective To investigate the relationship between breast cancer molecular classification and prognosis. Methods From January 2002 to December 2003, 708 female primary breast cancer patients with a mean age of 53 years old were retrospectively analyzed. The classification of breast cancer was according to the immunohistochemical results of estrogen receptor ( ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2) status. Molecular classification definitions included highly endocrine responsive, incompletely endocrine responsive, triple negative, and HER2 positive. The prognosis among different molecular classifications of breast cancer was investigated. The survival rates of different classifations were compared by Log-rank test. Results The proportion of highly endocrine responsive, incompletely endocrine responsive, HER2 positive and triple-negative breast cancer was 33.2% (235/708), 23. 6% ( 167/708), 21.3% (151/708) and 21.9% (155/708). The follow-up period were from 3 to 68 months with a median of 40. 2 months. A total of 100 cases were identified to had disease recurrence or death. Factors affecting the prognosis were tumor size, axillary lymph node status, molecular classification, adjuvant radiotherapy and adjuvant endocrine therapy by univariate analysis. Multivariate analysis revealed that the molecular classification and lymph node status were the independent prognostic factors with the hazard ratio 1. 205 ( P = 0. 047 ) and 4. 512 ( P = 0. 000 ), respectively. Survival analysis showed that highly endocrine responsive breast cancer was with superior prognosis versus others. Conclusions Molecular classification of breast cancer is an independent predictor of prognosis. Breast cancer patients classified as highly endocrine responsive subtype have the best outcome.
出处 《中华外科杂志》 CAS CSCD 北大核心 2008年第18期1400-1403,共4页 Chinese Journal of Surgery
关键词 乳腺肿瘤 预后 因素分析 统计学 Breast neoplasms Prognosis Factor analysis, statistical
  • 相关文献

参考文献13

  • 1Bear HD,Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 2006,24:2019-2027.
  • 2Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J C lin Oncol,2007 ,25 :5287-5312.
  • 3杨丽芳,宋三泰,李晓兵,江泽飞,刘晓晴,马维娜,乔西平,郭斯启.284例原发乳腺癌c-erbB2蛋白的表达及其与预后的关系[J].中华肿瘤杂志,2006,28(4):294-297. 被引量:11
  • 4Konecny G,Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst,2003, 95 : 142-153.
  • 5Slamon DJ,Godolphin W,Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science, 1989,244:707-712.
  • 6Perou CM, Sφrlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature ,2000,406:747-752.
  • 7Sφrlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Nail Acad Sci USA,2001,98:10869-10874.
  • 8Sφrlie T,Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A,2003,100:8418-8423.
  • 9Lohrisch C, Piccart M. An overview of HER2. Semin Oncol,2001, 28 Suppl 18:3-11.
  • 10Hartmann LC, Ingle JN, Wold LE, ct al. Prognostic value of cerbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer, 1994,74:2956-2963.

二级参考文献25

  • 1宋三泰 汤仲明 等.雌激素受体(ER)阳性乳癌的临床和病理特点的研究[J].中华肿瘤杂志,1985,7(6):426-428.
  • 2Gullick WJ, Srinivasan R. The type Ⅰ growth factor receptor family:new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat, 1998, 52: 43-53.
  • 3Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of e-erbB2 expression in breast cancer. J Surg Oncol, 2002, 79: 216-223.
  • 4Menard S, Forti S, Castiglioni F, et al. HER2 as a prognostic factorin breast cancer. Oncology, 2001,61 (Suppl 2):67-72.
  • 5Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol, 1997,15 : 2894-2904.
  • 6Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst, 2002, 94: 852-854.
  • 7Koneeny G, Pauletti G, Pegram M et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst, 2003,95 : 142-153.
  • 8Bevillion F, Bonneterre J, Peyrat JP. EBBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer, 1998, 34:791-808.
  • 9Menard S, Pupa. SM, Campiglio M, et al. Biologic and therapeutic role of HER2 in cancer. Oncogene, 2003, 22: 6570-6578.
  • 10Tan M, Yao J, Yu D. Overexpression of the c-erbB2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res, 1997, 57:1199-1205.

共引文献22

同被引文献155

引证文献14

二级引证文献93

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部